Bristol-Myers Squibb Stock Falls as Kidney Cancer Drug Fails
Survival rates without progression of the disease did not reach statistical significance.

Bristol-Myers Squibb Co. (BMY) shares were down 0.62% to $57.52 in early morning trading Wednesday after the company announced that its kidney cancer drug trial failed to show efficacy during trials. 

The company said that while patients responded well during the late-stage study of its kidney cancer drugs Opdivo and Yervoy, survival rates without progression of the disease did not reach statistical significance. 

Year to date, Bristol-Myers Squibb shares have fallen about 1%, and over the past 12 months, the stock has declined 0.74%. 

The stock was down about 1% at Wednesday's market open.

Watch More with TheStreet:

More from Stocks

Netflix, Amazon, Jerome Powell, Walmart and Microsoft - 5 Things You Must Know

Netflix, Amazon, Jerome Powell, Walmart and Microsoft - 5 Things You Must Know

Did Netflix Earnings Just Stomp Out Any Chance of a Big Market Rally?

Did Netflix Earnings Just Stomp Out Any Chance of a Big Market Rally?

3 Stocks Poised to Move the Markets This Week: Goldman Sachs, Microsoft, GE

3 Stocks Poised to Move the Markets This Week: Goldman Sachs, Microsoft, GE

Why Netflix Stock Is Still a Buy: Shark Tank Star Kevin O'Leary

Why Netflix Stock Is Still a Buy: Shark Tank Star Kevin O'Leary

Here's How Shark Tank Star Kevin O'Leary Decides What Stocks to Invest In

Here's How Shark Tank Star Kevin O'Leary Decides What Stocks to Invest In